Abstract
Neisseria meningitidis (the meningococcus) is a Gram-negative diplococcus, which causes meningitis and septicaemia with a high case fatality rate and many survivors suffering from long-term neurological and non-neurological complications. In Europe, it is typically a rare endemic disease, but hyperendemic and epidemic disease patterns also occur. Prevention of disease through vaccination is the only realistic prospect for disease control. Vaccines targeting five of the six disease-causing capsular groups (A, B, C, W and Y) are in use across Europe, with significant reductions in disease rates in the last two decades. Further developments such as the recent emergence of capsular group X in sub-Saharan Africa, for which there is currently no licensed vaccine, demonstrate that vaccine prevention of meningococcal disease is an ongoing and evolving challenge.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Further Reading
Agnememel A, Hong E, Giorgini D, Nunez-Samudio V, Deghmane AE, Taha MK. Neisseria meningitidis Serogroup X in Sub-Saharan Africa. Emerg Infect Dis 2016;22(4):698–702.
Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Schneider H, Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 1970;282(8):417–20.
Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nokleby H, Rosenqvist E, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338(8775):1093–6.
Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine 2005;23(17–18):2222–7.
Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010;10(12):853–61.
Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE, Centers for Disease and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1–28.
European Centre for Disease Prevention and Control. Surveillance atlas of infectious disease. Accessed 26th Jan 2021.
Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, Findlow J, Borrow R, Pizza M, Giuliani MM, Medini D. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 2013;31(43):4968–74.
Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, Zhujun S, Bhutta ZA, Abramson J. Global epidemiology of invasive meningococcal disease. Popul Health Metr 2013;11(1):17.
Kelly C, Arnold R, Galloway Y, O’Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007;166(7):817–23.
Kelly DF, Snape MD, Clutterbuck EA, Green S, Snowden C, Diggle L, Yu LM, Borkowski A, Moxon ER, Pollard AJ. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood 2006;108(8):2642–7.
Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, Bai X, Lucidarme J, Borrow R, Ramsay ME. Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England. NEJM 2020;382:309–317
Ladhani SN, Campbell H, Andrews N, Parikh SR, White J, Edelstein M, Clark SA, Lucidarme J, Borrow R, Ramsay ME. First real-world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease; prospective enhanced national surveillance, England, Clin Inf Dis 2020; https://doi.org/10.1093/cid/ciaa1244
Ladhani SN, Giuliani MM, Biolchi A, Pizza M, Beebeejaun K, Lucidarme J, Findlow J, Ramsay ME, Borrow R. Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England, Emerg Infect Dis 2016;22(2):309–11.
Maiden MC, Stuart JM, U. K. M. C. Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002;359(9320):1829–31.
Marshall HS, McMillan M, Koehler AP, Lawrence A, Sullivan TR, MacLennan JM, Maiden MCJ, Ladhani SN, Ramsay ME, Trotter C, Borrow R, Finn A, Kahler CM, Whelan J, Vadivelu K, Richmond P. Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia. NEJM 2020;382:318–327
Nainani V, Galal U, Buttery J, Snape MD. An increase in accident and emergency presentations for adverse events following immunisation after introduction of the group B meningococcal vaccine: an observational study. Arch Dis Child 2017;102:958–962.
Peltola H, Makela H, Kayhty H, Jousimies H, Herva E, Hallstrom K, Sivonen A, Renkonen OV, Pettay O, Karanko V, Ahvonen P, Sarna S. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977;297(13):686–91.
Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJ, Pollard AJ, Turner DP, Bazaz R, Ganguli A, Havelock T, Neal KR, Okike IO, Morales-Aza B, Patel K, Snape MD, Williams J, Gilchrist S, Gray SJ, Maiden MC, Toneatto D, Wang H, McCarthy M, Dull PM, Borrow R. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014;384(9960):2123–31.
Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, Casanueva GV, Rico CO, Rodriguez CR, Terry MH. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991;14(2):195–207; discussion 208–10
Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, Toneatto D, Pollard AJ. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010;29(11):e71–9.
Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008;299(2):173–84.
Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004;364(9431):365–7.
Vieusseux M. Memoire sur le maladie qui a regne a Geneva au printemps de 1805. J Med Clin Pharm 1805;11:163–82.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Pollard, A.J., Snape, M.D., Sadarangani, M. (2021). Meningococcal Vaccines. In: Vesikari, T., Van Damme, P. (eds) Pediatric Vaccines and Vaccinations. Springer, Cham. https://doi.org/10.1007/978-3-030-77173-7_22
Download citation
DOI: https://doi.org/10.1007/978-3-030-77173-7_22
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-77172-0
Online ISBN: 978-3-030-77173-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)